Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

Mining the Human Microbiome for Novel Therapeutics

EF 2016-17

Résumé
Our bodies are made up of as many or more bacterial cells than human. Most of these bacteria are beneficial (think probiotics) and our bodies can be considered something of an ecosystem. Like any ecosystem, events can occur that disrupt the balance of the members that make up our body's ecosystem (the microbiome). These events can be brought about by exposure to substances (antibiotic treatment), the food we eat, and pre-existing medical conditions, to name a few. Human conditions as far-ranging as psoriasis, obesity, colitis, and cardiovascular disease have all been implicated in microbiome imbalances. Bacterial-bacterial interactions and bacterial-human interactions must clearly play a massive part in such imbalances but the exact mechanisms by which these interactions occur remains elusive. However, it's well-established that bacteria communicate largely through the production and interchange of chemicals (think pheromones). These chemicals undoubtedly play a central role in bacterial interactions with us and other bacteria. Unfortunately, we are currently unable to culture most of these bacteria in question, let alone isolate the chemicals they produce. Luckily, recent advances in the sequencing of DNA have allowed us to discover the genes that encode production of these important molecules - think of the DNA as a blueprint. This project proposes to develop tools by which we can take these blueprints (in particular ones we think may encode potential drugs) and use common laboratory organisms (E. col or the yeast we use to make beer, for instance) to produce these chemicals. Because these chemicals are a part of our microbiome (they've evolved with us!) they are almost certain to have truly potent activities ranging from antibacterial to immunomodulatory. In addition to being a potential source of new drugs, discovery of these molecules will fill a crucial gap in our understanding between the composition of the human microbiome and disease.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
357803
Name
King Andrew M
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Mining the Human Microbiome for Novel Therapeutics
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Antibiotics And Resistance; Drug Discovery; Human Microbiome; Natural Products; Synthetic Biology
Abstract
Our bodies are made up of as many or more bacterial cells than human. Most of these bacteria are beneficial (think probiotics) and our bodies can be considered something of an ecosystem. Like any ecosystem, events can occur that disrupt the balance of the members that make up our body's ecosystem (the microbiome). These events can be brought about by exposure to substances (antibiotic treatment), the food we eat, and pre-existing medical conditions, to name a few. Human conditions as far-ranging as psoriasis, obesity, colitis, and cardiovascular disease have all been implicated in microbiome imbalances. Bacterial-bacterial interactions and bacterial-human interactions must clearly play a massive part in such imbalances but the exact mechanisms by which these interactions occur remains elusive. However, it's well-established that bacteria communicate largely through the production and interchange of chemicals (think pheromones). These chemicals undoubtedly play a central role in bacterial interactions with us and other bacteria. Unfortunately, we are currently unable to culture most of these bacteria in question, let alone isolate the chemicals they produce. Luckily, recent advances in the sequencing of DNA have allowed us to discover the genes that encode production of these important molecules - think of the DNA as a blueprint. This project proposes to develop tools by which we can take these blueprints (in particular ones we think may encode potential drugs) and use common laboratory organisms (E. col or the yeast we use to make beer, for instance) to produce these chemicals. Because these chemicals are a part of our microbiome (they've evolved with us!) they are almost certain to have truly potent activities ranging from antibacterial to immunomodulatory. In addition to being a potential source of new drugs, discovery of these molecules will fill a crucial gap in our understanding between the composition of the human microbiome and disease.
Competitiondate
201609
Approvedterm2
2 yrs 0 mth
Pinamesdelim
King, Andrew M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~